Active Ingredient(s):Sodium Phenylbutyrate FDA Approved: * June 17, 2022 Pharm Company: *MEDUNIK Category:Hyperammonemia
Sodium phenylbutyrate is a salt of an aromatic fatty acid, 4-phenylbutyrate (4-PBA) or 4-phenylbutyric acid. The compound is used to treat urea cycle disorders, because its metabolites offer an alternative pathway to the urea cycle to allow excretion of excess nitrogen. It is an orphan drug, marketed by Ucyclyd Pharma under the trade name Buphenyl, by Swedish Orphan International (Sweden) as Ammonaps, aby Fyrlklövern Scandinavia as...
* May have multiple approval dates, manufacturers, or labelers.